For: | Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598 [PMID: 28031776 DOI: 10.4239/wjd.v7.i20.572] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v7/i20/572.htm |
Number | Citing Articles |
1 |
Fernando Mendonça, Raquel Soares, Davide Carvalho, Paula Freitas. The Impact of Bariatric Surgery on Bone Health: State of the Art and New Recognized Links. Hormone and Metabolic Research 2022; 54(03): 131 doi: 10.1055/a-1767-5581
|
2 |
Victoria Wen Wei Ng, Gheslynn Gerard, Jonathan Jin Kai Koh, Kah Yin Loke, Yung Seng Lee, Nicholas Beng Hui Ng. The role of glucagon‐like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review. Clinical Obesity 2024; 14(3) doi: 10.1111/cob.12642
|
3 |
Ayşen Akkurt Kocaeli. Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity. Cureus 2023; doi: 10.7759/cureus.50544
|
4 |
Runzhi Zeng, Yijia Zeng, Qi Wang, Xinzhang Li, Jize Liu, Bingjun Li, Guangyong Zhang, Sanyuan Hu. Sleeve gastrectomy decreased hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. Biochemical and Biophysical Research Communications 2023; 653: 115 doi: 10.1016/j.bbrc.2023.02.071
|
5 |
Simona Ferjan, Andrej Janez, Mojca Jensterle. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study. Metabolic Syndrome and Related Disorders 2017; 15(10): 515 doi: 10.1089/met.2017.0095
|
6 |
Ananyaa Sridhar, Dawood Khan, Gayathri Babu, Nigel Irwin, Victor A. Gault, Peter R. Flatt, Charlotte R. Moffett. Chronic exposure to incretin metabolites GLP-1(9−36) and GIP(3−42) affect islet morphology and beta cell health in high fat fed mice. Peptides 2024; 178: 171254 doi: 10.1016/j.peptides.2024.171254
|
7 |
Midean Ismail, Samuel Stagling, Anna Lundberg, Fredrik H. Nystrom. A cross-over study of postprandial effects from moist snuff and red wine on metabolic rate, appetite-related hormones and glucose. Drug and Alcohol Dependence 2022; 236: 109479 doi: 10.1016/j.drugalcdep.2022.109479
|
8 |
Sidar Copur, Cem Tanriover, Furkan Yavuz, Katherine R. Tuttle, Mehmet Kanbay. Tirzepatide and potential use for metabolically healthy obesity. European Journal of Internal Medicine 2023; 113: 1 doi: 10.1016/j.ejim.2023.05.012
|
9 |
Kalie L. Tommerdahl, Alexander J. Kula, Petter Bjornstad. Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions. Expert Opinion on Pharmacotherapy 2023; 24(8): 913 doi: 10.1080/14656566.2023.2203319
|
10 |
Madison Failor, Mark Bohler, Chang Cao, Elizabeth Gilbert, Mark Cline. Elucidating the central anorexigenic mechanism of glucagon-like peptide 1 in Japanese quail (Coturnix japonica). General and Comparative Endocrinology 2023; 339: 114292 doi: 10.1016/j.ygcen.2023.114292
|
11 |
Dragan Micić, Snežana Polovina, Dušan Micić. The role of anti-obesity drugs in the management of obese diabetics. Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma 2018; 23(71): 15 doi: 10.5937/MedGla1870015M
|
12 |
Eduardo Sima, Dominic-Luc Webb, Per M. Hellström, Magnus Sundbom. Non-responders After Gastric Bypass Surgery for Morbid Obesity: Peptide Hormones and Glucose Homeostasis. Obesity Surgery 2019; 29(12): 4008 doi: 10.1007/s11695-019-04089-8
|
13 |
Donald E. Greydanus, Marisha Agana, Manmohan K. Kamboj, Saad Shebrain, Neelkamal Soares, Ransome Eke, Dilip R. Patel. Pediatric obesity: Current concepts. Disease-a-Month 2018; 64(4): 98 doi: 10.1016/j.disamonth.2017.12.001
|
14 |
Laura Bertoccini, Marco Giorgio Baroni. Diabetes: from Research to Clinical Practice. Advances in Experimental Medicine and Biology 2020; 1307: 193 doi: 10.1007/5584_2020_494
|
15 |
Sergio Santoro, Almino Ramos. The Questionable IFSO Position Statement. Obesity Surgery 2023; 33(2): 665 doi: 10.1007/s11695-022-06407-z
|
16 |
Qiming Tan, Camila E. Orsso, Edward C. Deehan, Lucila Triador, Catherine J. Field, Hein Min Tun, Joan C. Han, Timo D. Müller, Andrea M. Haqq. Current and emerging therapies for managing hyperphagia and obesity in Prader‐Willi syndrome: A narrative review. Obesity Reviews 2020; 21(5) doi: 10.1111/obr.12992
|
17 |
Taichi Nagahisa, Yoshifumi Saisho. Cardiorenal Protection: Potential of SGLT2
Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2
Diabetes. Diabetes Therapy 2019; 10(5): 1733 doi: 10.1007/s13300-019-00680-5
|
18 |
Eva Madrid, Miranda Ocara Vargas, Catalina Contreras-Vera, Cristina Saldías, Camila Micaela Escobar Liquitay, Victoria Novik A, Sergio R Munoz, Javier Bracchiglione. Glucagon-like peptide-1 analogues for overweight or obese adults. Cochrane Database of Systematic Reviews 2022; 2022(9) doi: 10.1002/14651858.CD015092
|
19 |
Chooi Yeng Lee. A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.748477
|
20 |
Nicholas Beng Hui Ng, Yue Wey Low, Dimple Dayaram Rajgor, Jia Ming Low, Yvonne Yijuan Lim, Kah Yin Loke, Yung Seng Lee. The effects of glucagon‐like peptide (GLP)‐1 receptor agonists on weight and glycaemic control in Prader–Willi syndrome: A systematic review. Clinical Endocrinology 2022; 96(2): 144 doi: 10.1111/cen.14583
|
21 |
Kalie L. Tommerdahl, Kristen J. Nadeau, Petter Bjornstad. Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists. Advances in Chronic Kidney Disease 2021; 28(4): 337 doi: 10.1053/j.ackd.2021.06.001
|
22 |
Mette Kruse Klausen, Mathias Ebbesen Jensen, Marco Møller, Nina Le Dous, Anne-Marie Østergaard Jensen, Victoria Alberte Zeeman, Claas-Frederik Johannsen, Alycia Lee, Gerda Krog Thomsen, Julian Macoveanu, Patrick MacDonald Fisher, Matthew Paul Gillum, Niklas Rye Jørgensen, Marianne Lerbæk Bergmann, Henrik Enghusen Poulsen, Ulrik Becker, Jens Juul Holst, Helene Benveniste, Nora D. Volkow, Sabine Vollstädt-Klein, Kamilla Woznica Miskowiak, Claus Thorn Ekstrøm, Gitte Moos Knudsen, Tina Vilsbøll, Anders Fink-Jensen. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight 2022; 7(19) doi: 10.1172/jci.insight.159863
|
23 |
James P. Psaltis, Jessica A. Marathe, Mau T. Nguyen, Richard Le, Christina A. Bursill, Chinmay S. Marathe, Adam J. Nelson, Peter J. Psaltis. Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future. Medicinal Research Reviews 2024; doi: 10.1002/med.22070
|
24 |
Yolanda Diz-Chaves, Salvador Herrera-Pérez, Lucas C. González-Matías, José Antonio Lamas, Federico Mallo. Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress. Nutrients 2020; 12(11): 3304 doi: 10.3390/nu12113304
|
25 |
Cem Tanriover, Sidar Copur, Abduzhappar Gaipov, Batu Ozlusen, Rustu E. Akcan, Masanari Kuwabara, Mads Hornum, Daniel H. Van Raalte, Mehmet Kanbay. Metabolically healthy obesity: Misleading phrase or healthy phenotype?. European Journal of Internal Medicine 2023; 111: 5 doi: 10.1016/j.ejim.2023.02.025
|
26 |
A. Sridhar, D. Khan, P.R. Flatt, N. Irwin, R.C. Moffett. PYY (3-36) protects against high fat feeding induced changes of pancreatic islet and intestinal hormone content and morphometry. Biochimica et Biophysica Acta (BBA) - General Subjects 2023; 1867(6): 130359 doi: 10.1016/j.bbagen.2023.130359
|
27 |
Chooi Yeng Lee. Effects of dietary vitamins on obesity-related metabolic parameters. Journal of Nutritional Science 2023; 12 doi: 10.1017/jns.2023.30
|
28 |
Wenxuan Di, Yuchen Zhang, Xinyuan Zhang, Luxuan Han, Liang Zhao, Yanling Hao, Zhengyuan Zhai. Heterologous expression of P9 from Akkermansia muciniphila increases the GLP-1 secretion of intestinal L cells. World Journal of Microbiology and Biotechnology 2024; 40(7) doi: 10.1007/s11274-024-04012-z
|
29 |
Tom Doyle. Core Trainee Prize Winner: Weight loss drugs: their role and potential future in orthopaedic surgery. Bone & Joint 360 2024; 13(3): 12 doi: 10.1302/2048-0105.133.360143
|
30 |
A. Y. Babenko, G. A. Matveev, T. I. Alekseenko, I. V. Derevitskii, M. A. Kokina, E. V. Shlyakhto. Interrelations of components of metabolic syndrome with the level of the hormones involved in regulation of adipose tissue metabolism. "Arterial’naya Gipertenziya" ("Arterial Hypertension") 2020; 25(6): 639 doi: 10.18705/1607-419X-2019-25-6-639-652
|
31 |
Joanna Michałowska, Ewa Miller-Kasprzak, Paweł Bogdański. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients 2021; 13(2): 351 doi: 10.3390/nu13020351
|
32 |
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, Georgios Germanidis. How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. Cancers 2022; 14(19): 4651 doi: 10.3390/cancers14194651
|
33 |
Mohsan Subhani, Ashwin Dhanda, James A. King, Fiona C. Warren, Siobhan Creanor, Melanie J. Davies, Sally Eldeghaidy, Stephen Bawden, Penny A. Gowland, Ramon Bataller, Justin Greenwood, Stephen Kaar, Neeraj Bhala, Guruprasad P. Aithal. Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review. eClinicalMedicine 2024; : 102920 doi: 10.1016/j.eclinm.2024.102920
|
34 |
John Donlon, Patrick Ryan. Peptidylglycine monooxygenase activity of monomeric species of growth hormone. Heliyon 2019; 5(9): e02436 doi: 10.1016/j.heliyon.2019.e02436
|
35 |
Sara C. Pereira, Ana C. Martins, Bruno P. Moreira, Raquel L. Bernardino, Alberto Barros, Mariana P. Monteiro, Pedro F. Oliveira, Marco G. Alves. Obesity‐related genes are expressed in human Sertoli cells and modulated by energy homeostasis regulating hormones. Journal of Cellular Physiology 2021; 236(7): 5265 doi: 10.1002/jcp.30230
|
36 |
Tianxing Li, Minjian Liang, Jianming Luo, Xichun Peng. Metabolites of Clostridium leptum fermenting flaxseed polysaccharide alleviate obesity in rats. International Journal of Biological Macromolecules 2024; 264: 129907 doi: 10.1016/j.ijbiomac.2024.129907
|
37 |
Olga Giménez-Palop, Ana Romero, Laia Casamitjana, Rocio Pareja, Mercedes Rigla, Assumpta Caixàs. Effect of semaglutide on weight loss and glycaemic control in patients with Prader–Willi Syndrome and type 2 diabetes. Endocrinología, Diabetes y Nutrición 2024; 71(2): 83 doi: 10.1016/j.endinu.2023.12.009
|
38 |
Ghinwa M. Barakat, Wiam Ramadan, Ghaith Assi, Noura B. El Khoury. Satiety: a gut–brain–relationship. The Journal of Physiological Sciences 2024; 74(1) doi: 10.1186/s12576-024-00904-9
|
39 |
Hayyam Babayev, Sevil Arabaci-Tamer, Alper Yildirim, Damla Kayali, Feriha Ercan, Cumhur Yegen, M. Umit Ugurlu, Berrak Ç. Yeğen. Sleeve gastrectomy–induced endocrine changes in the remnant stomachs of premenopausal and postmenopausal rats: role of the estrogen receptors. Surgery for Obesity and Related Diseases 2021; 17(1): 193 doi: 10.1016/j.soard.2020.08.011
|
40 |
Nedaa Skeik, Sewar A Elejla, Anish Sethi, Jesse Manunga, Aleem Mirza. Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. Vascular Medicine 2023; 28(1): 62 doi: 10.1177/1358863X221143811
|
41 |
Radica Z. Alicic, Emily J. Cox, Joshua J. Neumiller, Katherine R. Tuttle. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nature Reviews Nephrology 2021; 17(4): 227 doi: 10.1038/s41581-020-00367-2
|
42 |
Felix Hofer, Niema Kazem, Ronny Schweitzer, Andreas Hammer, Friedrich Jakse, Lorenz Koller, Christian Hengstenberg, Patrick Sulzgruber, Alexander Niessner. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease. Cardiovascular Drugs and Therapy 2021; 35(6): 1161 doi: 10.1007/s10557-021-07160-8
|
43 |
Laura C. Page, Mark D. Miller, David D’Alessio, Jenny Tong. Pediatric Obesity. Contemporary Endocrinology 2018; : 43 doi: 10.1007/978-3-319-68192-4_3
|
44 |
Mageshwaran Lakshmanan. Introduction to Basics of Pharmacology and Toxicology. 2021; : 741 doi: 10.1007/978-981-33-6009-9_47
|
45 |
Faraaz Ali Shah, Srikanth Singamsetty, Lanping Guo, Byron W. Chuan, Sherie McDonald, Bryce A. Cooper, Brett J. O'Donnell, Darko Stefanovski, Burton Wice, Yingze Zhang, Christopher P. O'Donnell, Bryan J. McVerry. Stimulation of the endogenous incretin glucose-dependent insulinotropic peptide by enteral dextrose improves glucose homeostasis and inflammation in murine endotoxemia. Translational Research 2018; 193: 1 doi: 10.1016/j.trsl.2017.11.001
|
46 |
Masoud Nouri-Vaskeh, Neda Khalili, Amirreza Khalaji, Pouya Behnam, Leila Alizadeh, Sara Ebrahimi, Neda Gilani, Mehdi Mohammadi, Seyed Alisalar Madinehzadeh, Mohammad Zarei. Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. Archives of Physiology and Biochemistry 2023; 129(2): 373 doi: 10.1080/13813455.2020.1828479
|
47 |
Kalie L. Tommerdahl, Jessica Kendrick, Petter Bjornstad. The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology 2022; 17(6): 905 doi: 10.2215/CJN.00020122
|
48 |
Edward S Jones, Nicolas Nunn, Adam P Chambers, Søren Østergaard, Birgitte S Wulff, Simon M Luckman. Modified Peptide YY Molecule Attenuates the Activity of NPY/AgRP Neurons and Reduces Food Intake in Male Mice. Endocrinology 2019; 160(11): 2737 doi: 10.1210/en.2019-00100
|
49 |
Olga Giménez-Palop, Ana Romero, Laia Casamitjana, Rocio Pareja, Mercedes Rigla, Assumpta Caixàs. Effect of semaglutide on weight loss and glycaemic control in patients with Prader–Willi Syndrome and type 2 diabetes. Endocrinología, Diabetes y Nutrición (English ed.) 2024; 71(2): 83 doi: 10.1016/j.endien.2023.12.001
|
50 |
Erina Albinsson-Stenholm, Johannes Bergsén, Simon Ingves, Nathalie Vilhelmsson, Hans Guldbrand, Fredrik H Nystrom. Subjects with high fasting insulin also have higher postprandial GLP-1 and glucagon levels than controls with lower insulin. Nutrition Research 2019; 72: 111 doi: 10.1016/j.nutres.2019.10.009
|
51 |
Jan Miroslav Hartinger. Novel drugs in pharmacotherapy of obesity. Praktické lékárenství 2021; 17(2): 74 doi: 10.36290/lek.2021.015
|
52 |
Emma Custers, Ayla Franco, Amanda Kiliaan. Bariatric Surgery and Gut-Brain-Axis Driven Alterations in Cognition and Inflammation. Journal of Inflammation Research 2023; : 5495 doi: 10.2147/JIR.S437156
|